Načítá se...
Biosimilars: How Can Payers Get Long-Term Savings?
The term ‘biosimilar’ refers to an alternative similar version of an off-patent innovative originator biotechnology product (the ‘reference product’). Several biosimilars have been approved in Europe, and a number of top-selling biological medicines have lost, or will lose, patent protection over th...
Uloženo v:
| Vydáno v: | Pharmacoeconomics |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4863918/ https://ncbi.nlm.nih.gov/pubmed/26792791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-015-0380-x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|